Dr. Joel Neal from Stanford Cancer Institute joined GO2’s January Lung Cancer Living Room® to explain what good practice looks like when diagnosing and treating lung cancer and that there is no “one size fits all” approach to treatment. [...]
Question: I am interested in learning more about clinical trials as a treatment option for my lung cancer. How do I know if I am eligible? How can I find a clinical trial that is a good fit for [...]
With recent advancements made in thoracic oncology, the management of non-small cell lung cancer (NSCLC) is evolving rapidly. While chemotherapy, immunotherapy, targeted therapy, molecular testing, and radiotherapy continue to play a large role in the management of lung cancer, [...]
Question: I was recently diagnosed with lung cancer and am on my first line of treatment. I keep hearing that at some point I may develop a resistance to that treatment. What exactly does that mean and how long [...]
Author: Renee Botello, MSc, Navigator, Treatment and Trials, GO2 for Lung Cancer With decades of research and advances in precision medicine, scientists continue to broaden the treatment standards and options for patients with non-small cell lung cancer (NSCLC). By [...]
Many people being treated for lung cancer will eventually develop resistance to their current therapies, causing them to stop working. When this happens, and a person’s cancer starts to progress on their current treatment, their healthcare team will take [...]
Question: I’ve just been diagnosed with lung cancer, and my doctor said I may need to have surgery. What can I expect? Answer: Your healthcare team will explain the best type of surgery for you, but the goal will [...]
On October 11, 2023, the U.S. Food and Drug Administration (FDA) approved a combination of Braftovi (encorafenib) and Mektovi (binimetinib) for people with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation. BRAF is a less common [...]
Question: What is the difference between neo-adjuvant therapy and adjuvant therapy? Answer: “Neo-adjuvant” and “adjuvant” are terms used in the context of cancer treatment to refer to therapies that are given before or after the primary treatment, such as surgery [...]
Small cell lung cancer (SCLC), which represents about 15% of all lung cancer diagnoses, is an often-aggressive form of lung cancer that has historically been difficult to treat. However, the science driving new treatments for SCLC is moving faster than [...]